EPPP: Part 1, Knowledge Quiz: Medication Mechanisms

What this quiz covers

This quiz focuses on Medication Mechanisms, giving you a quick way to practice the rules, question types, and explanations that matter most for EPPP: Part 1, Knowledge.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Enhancing GABA-A currents
2. Blocking D2 dopamine receptors
3. Blocking serotonin reuptake
4. Blocking sodium ion channels (correct answer)

Question 2

1. Cytochrome P450 2D6 inhibition
2. Monoamine oxidase inhibition (correct answer)
3. Blockade of NMDA receptors
4. GABA-A receptor potentiation

Question 3

1. Blockade of dopamine reuptake (correct answer)
2. Vesicular transport reversal
3. Inhibiting monoamine oxidase B
4. D2 receptor partial agonism

Question 4

1. GABA-A positive modulation
2. Partial agonism at 5-HT1A (correct answer)
3. Alpha-2-delta calcium blockade
4. Beta-adrenergic antagonism

Question 5

1. Blocks muscarinic receptors
2. Enhances GABAergic inhibition
3. Antagonizes 5-HT2A receptors (correct answer)
4. Stimulates dopamine release

Question 6

1. Atypical antipsychotics have higher affinity for serotonin 5-HT2A receptors relative to dopamine D2 receptors, providing neuroprotective effects in motor pathways (correct answer)
2. Atypical antipsychotics selectively block dopamine receptors in limbic regions while sparing the nigrostriatal pathway responsible for motor control functions
3. Atypical antipsychotics enhance acetylcholine release in the basal ganglia, which counteracts dopamine blockade and maintains motor function balance
4. Atypical antipsychotics have intrinsic partial agonist activity at dopamine receptors, preventing complete blockade and preserving baseline motor coordination

Question 7

1. Methylphenidate blocks dopamine and norepinephrine reuptake transporters, increasing these neurotransmitters' availability in prefrontal cortical regions (correct answer)
2. Methylphenidate acts as a direct agonist at alpha-2 adrenergic receptors, enhancing inhibitory control mechanisms in frontal executive networks
3. Methylphenidate selectively inhibits serotonin reuptake while modulating GABA-mediated inhibition in attention and impulse control circuits
4. Methylphenidate enhances acetylcholine synthesis and release, improving cholinergic neurotransmission essential for sustained attention and working memory

Question 8

1. Alprazolam's rapid onset of action due to high lipophilicity and quick brain penetration, combined with relatively short half-life requiring frequent dosing (correct answer)
2. Alprazolam's selective binding to GABA-A receptor α1 subunits provides panic-specific anxiolysis while minimizing sedation and cognitive impairment
3. Alprazolam's active metabolites have longer half-lives than the parent compound, providing sustained anxiolytic effects without peak-trough variations
4. Alprazolam's high protein binding affinity results in slow release from tissue stores, providing gradual onset but prolonged therapeutic effects

Question 9

1. Lithium blocks voltage-gated sodium channels, preventing rapid neuronal firing patterns associated with mood episode initiation and propagation
2. Lithium inhibits inositol monophosphatase and glycogen synthase kinase-3β, modulating intracellular signaling cascades involved in mood regulation (correct answer)
3. Lithium enhances GABA-mediated inhibition by increasing GABA synthesis and reducing GABA metabolism in mood-regulating brain circuits
4. Lithium acts as a dopamine D2 receptor antagonist while simultaneously blocking serotonin 5-HT2A receptors in limbic structures

Question 10

1. Pramipexole acts as a dopamine D2/D3 receptor agonist, improving motor function while D3 stimulation in limbic areas contributes to antidepressant effects (correct answer)
2. Pramipexole blocks dopamine reuptake while simultaneously inhibiting serotonin metabolism, providing both motor improvement and mood stabilization
3. Pramipexole enhances acetylcholine synthesis in the striatum while blocking norepinephrine reuptake in prefrontal cortical regions
4. Pramipexole modulates GABA-A receptors in motor circuits while acting as a partial agonist at serotonin 5-HT1A receptors in mood pathways

Question 11

1. First-generation antihistamines such as diphenhydramine and hydroxyzine, which cross the blood-brain barrier and block central histamine receptors
2. Tricyclic antidepressants such as amitriptyline and doxepin, which have significant antihistaminergic properties in addition to monoamine reuptake inhibition (correct answer)
3. Z-drugs such as zolpidem and eszopiclone, which selectively target specific GABA-A receptor subunits while avoiding histaminergic side effects
4. Benzodiazepines such as lorazepam and clonazepam, which enhance GABA-mediated chloride influx through positive allosteric modulation mechanisms

Question 12

1. Benzodiazepines, which enhance GABA-A receptor function and provide rapid anxiolytic effects through chloride channel modulation
2. Anticonvulsants such as carbamazepine and lamotrigine, which stabilize neuronal membranes and prevent rapid firing associated with mood episodes (correct answer)
3. Atypical antipsychotics, which block dopamine D2 receptors and modulate serotonin 5-HT2A receptors to control psychotic and mood symptoms
4. Lithium compounds, which interfere with inositol phosphate signaling cascades and modulate glycogen synthase kinase-3 beta activity

Question 13

1. MAOIs irreversibly bind to and inactivate the enzymes responsible for breaking down monoamine neurotransmitters in the synaptic cleft (correct answer)
2. MAOIs selectively block the reuptake of serotonin at the presynaptic terminal while having minimal effect on other neurotransmitter systems
3. MAOIs function as direct agonists at dopamine and norepinephrine receptors, bypassing the need for endogenous neurotransmitter release
4. MAOIs enhance the synthesis of monoamine neurotransmitters by upregulating the expression of rate-limiting enzymatic pathways

Question 14

1. Bupropion acts as a selective norepinephrine and dopamine reuptake inhibitor with minimal direct effects on serotonergic neurotransmission pathways (correct answer)
2. Bupropion functions as a partial agonist at serotonin 5-HT1A receptors while simultaneously blocking histamine H1 receptors in limbic regions
3. Bupropion enhances GABA-mediated inhibition through positive allosteric modulation of GABA-A receptors in cortical and subcortical areas
4. Bupropion blocks voltage-gated calcium channels and modulates glutamate release at excitatory synapses throughout the central nervous system

Question 15

1. Fluoxetine
2. Lithium (correct answer)
3. Risperidone
4. Diazepam

Question 16

1. Atomoxetine selectively inhibits norepinephrine reuptake without affecting dopamine transporters, providing therapeutic benefits with less abuse potential (correct answer)
2. Atomoxetine acts as a partial agonist at dopamine D4 receptors while blocking histamine H1 receptors, improving attention without stimulant effects
3. Atomoxetine enhances acetylcholine release in the prefrontal cortex while inhibiting GABA metabolism, providing cognitive enhancement without euphoria
4. Atomoxetine blocks voltage-gated potassium channels in attention networks while sparing reward circuits, avoiding addiction potential of dopaminergic stimulation

Question 17

1. Pregabalin enhances GABA neurotransmission by acting as a positive allosteric modulator at GABA-A receptor complexes throughout the limbic system
2. Pregabalin blocks voltage-gated calcium channels containing the α2δ subunit, reducing excitatory neurotransmitter release at presynaptic terminals (correct answer)
3. Pregabalin inhibits the reuptake of both serotonin and norepinephrine while having minimal effects on dopaminergic neurotransmission pathways
4. Pregabalin acts as a partial agonist at GABA-B receptors, modulating inhibitory tone and reducing hyperexcitability in anxiety circuits

Question 18

1. Benzodiazepines act as positive allosteric modulators at GABA-A receptors, enhancing chloride influx and causing rapid but adaptable changes in receptor sensitivity (correct answer)
2. Benzodiazepines directly activate GABA-B receptors while simultaneously blocking glutamate NMDA receptors, creating immediate but unsustainable neurotransmitter balance
3. Benzodiazepines inhibit GABA metabolism by blocking GABA transaminase, leading to GABA accumulation and subsequent downregulation of synthesis
4. Benzodiazepines enhance acetylcholine release in the basal forebrain while blocking dopamine reuptake, producing anxiolytic effects through multiple neurotransmitter systems

Question 19

1. Initial serotonin reuptake blockade activates 5-HT2A and 5-HT2C receptors before adaptive downregulation occurs, potentially causing agitation (correct answer)
2. SSRIs initially inhibit dopamine release through serotonin-dopamine interactions, causing compensatory norepinephrine hyperactivity and anxiety symptoms
3. SSRIs block voltage-gated calcium channels during the first weeks of treatment, disrupting normal neuronal firing patterns and causing activation
4. SSRIs enhance glutamate release before GABA compensatory mechanisms develop, creating temporary excitatory-inhibitory imbalance and activation symptoms

Question 20

1. Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and decreasing excitatory neurotransmitter release in pain pathways (correct answer)
2. Gabapentin directly activates GABA-B receptors in the dorsal horn of the spinal cord, enhancing inhibitory control over pain signal transmission
3. Gabapentin blocks sodium channels in peripheral nociceptors, preventing action potential propagation and reducing pain signal generation at injury sites
4. Gabapentin inhibits cyclooxygenase enzymes while simultaneously blocking NMDA glutamate receptors, providing dual anti-inflammatory and neuroprotective effects